25.11.2022 Cannovum AG  DE000A2LQU21

EQS-News: Cannovum AG expands management board


EQS-News: Cannovum AG / Key word(s): Personnel
Cannovum AG expands management board

25.11.2022 / 13:07 CET/CEST
The issuer is solely responsible for the content of this announcement.

Berlin, 25.11.2022 - Cannovum AG (stock exchanges Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) expands its Management Board. The new board position of the first German fully licensed cannabis company on the stock exchange will be taken over by Klaus Madzia as of 25.11.2022. The long-time journalist and communications expert has been Chief Marketing Officer (CMO) for Cannovum AG since September 2022.


"We are very pleased to have Klaus Madzia, an experienced media and marketing professional, on the board," says Pia Marten, board member and co-founder of Cannovum AG. Marten adds, "With him, we can further expand our strong position for the legalization of the stimulant market and thus powerfully advance the cannabis revolution."


Klaus Madzia: "This is a unique opportunity: a new market worth billions is emerging in Europe. Cannabis is becoming the recreational choice of a young, innovative generation. Cannovum AG stands ready to become a major player in this emerging segment."


Klaus Madzia has worked as a journalist, editor-in-chief, and content director in various positions in Germany and Europe over the past 20 years. After starting as an editor at the news magazine DER SPIEGEL, he held positions at the media houses Condé Nast, Burda and Handelsblatt. Thanks to his many years of consulting work for Wort und Bild Verlag, the 55-year-old is very familiar with the digitization of the healthcare system.




Klaus Madzia, IR & PR, Cannovum AG

Phone +49 30 3982 163 62, [email protected]


Cannovum AG is the first German fully licensed cannabis company to be listed on the stock exchange. The shares are traded on the Düsseldorf, Munich, Berlin, Hamburg and gettex stock exchanges. Through its subsidiary Cannovum Health eG, it is a fully licensed pharmaceutical wholesaler, importer, and manufacturer of high-quality medical cannabis products based in Berlin. Cannovum AG is ready for the legalization of cannabis and well prepared: for sales through pharmacies as well as through licensed specialty stores and online shipping. Cannovum AG is already a market leader in the medical cannabis sector.

Currently, the company is active in the importation of high-quality cannabinoid precursors, medical-scientific education and nationwide distribution for a simplified and equitable access to cannabis-based therapies.


For more information, visit www.cannovum.de




25.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language: English
Company: Cannovum AG
Rheinsberger Str. 76/77
10115 Berlin
Phone: +49 (0)30 3982 16360
E-mail: [email protected]
Internet: www.cannovum.com
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich
EQS News ID: 1497791

End of News EQS News Service

1497791  25.11.2022 CET/CEST


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 0,00 0,00 0,00 0,09 0,00 0,00 0,00
EBITDA1,2 0,00 0,00 0,00 -0,05 -0,03 -0,11 0,00
EBITDA-Marge3 0,00 0,00 0,00 -55,56 0,00 0,00 0,00
EBIT1,4 0,00 0,00 0,00 -0,05 -0,03 -0,11 0,00
EBIT-Marge5 0,00 0,00 0,00 -55,56 0,00 0,00 0,00
Jahresüberschuss1 0,00 0,00 0,00 -0,05 -0,03 -0,11 0,00
Netto-Marge6 0,00 0,00 0,00 -55,56 0,00 0,00 0,00
Cashflow1,7 0,00 0,00 0,00 -0,05 -0,03 -0,11 0,00
Ergebnis je Aktie8 0,00 0,00 0,00 0,00 0,00 -0,04 -0,06
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: M&B Treuhand

WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2LQU2 4,985 Halten 11,90
KGV 2024e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
38,35 0,00 0,00 -498,50
1,03 - 0,00 -110,14
Dividende '22 in € Dividende '23e in € Div.-Rendite '22e
in %
0,00 0,00 0,00 12.07.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
30.09.2022 30.06.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-2,47% -3,20% 1,73% -20,32%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Cannovum AG  ISIN: DE000A2LQU21 können Sie bei EQS abrufen

Handel , A2LQU2 , 27N